San Diego biotech that's trying to treat rare genetic diseases is acquired by Novartis
The acquisition of DTx Pharma by drug giant Novartis includes the potential for an additional $500 million payout depending on reaching certain pre-determined milestones
Source: sandiegouniontribune.com